Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
American Journal of Clinical Oncology|October 10, 2021
Treatment and Prevention of Brain Metastases in Small Cell Lung CancerRebekah Rittberg, Shantanu Banerji, Julian O Kim, et al.
Cureus|December 3, 2020
Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF MutationRebekah Rittberg, Shantanu Banerji, Susan Green, et al.
Current Oncology (Toronto, Ont.)|March 11, 2021
Canadian Cancer Centre Response to COVID-19 Pandemic: A National and Provincial ResponseRebekah Rittberg, Anmol Mann, Danielle Desautels, et al.
Clinical Lung Cancer|March 22, 2020
Effect of Hospitalization During First Chemotherapy and Performance Status on Small-cell Lung Cancer OutcomesRebekah Rittberg, Susan Green, Trevor Aquin, et al.
Journal of Geriatric Oncology|August 17, 2020
Utility of the modified frailty index in predicting toxicity and cancer outcomes for older adults with advanced pancreatic cancer receiving first-line palliative chemotherapyRebekah Rittberg, Hanbo Zhang, Pascal Lambert, et al.
American Journal of Clinical Oncology|January 24, 2022
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative ChemotherapyErin N McAndrew, Hanbo Zhang, Pascal Lambert, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic TherapyRebekah Rittberg, Bonnie Leung, Aria Shokoohi, et al.
Journal of Geriatric Oncology|January 14, 2024
Impact of age, comorbidity, and polypharmacy on receipt of systemic therapy in advanced cancers: A retrospective population-based studyRebekah Rittberg, Kathleen Decker, Pascal Lambert, et al.
Current Oncology (Toronto, Ont.)|February 4, 2021
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRDRebekah Rittberg, Craig Harlos, Heidi Rothenmund, et al.
Current Oncology (Toronto, Ont.)|November 24, 2022
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly DosingLauren Jones, Rebekah Rittberg, Bonnie Leung, et al.
Pageof 3